Gerald Treiman, IRB Chair John Stillman, IRB Director Maureen Brinkman, IRB Administrator Ann Johnson, IRB Administrator.

Slides:



Advertisements
Similar presentations
The Role of the IRB An Institutional Review Board (IRB) is a review committee established to help protect the rights and welfare of human research subjects.
Advertisements

What FDA Looks for When Inspecting IRBs and Sponsors Marian J. Serge Nurse Consultant Division of Bioresearch Monitoring Office of Compliance Center for.
The HRPP FYI Process and the UPIRSO/SAE Review Sheet An IRB Infoshort February 2014.
What is a Data and Safety Monitoring Plan and how do I get one? Presented by Office of Human Research Protection.
Protocol Deviations : Identification, Responses and Solutions The Office of Human Subjects Research’s Compliance Monitoring Program Educational Seminars:
SOP Melody Lin, Ph.D. Deputy Director, Office for Human Research Protections Director, International Activities Santiago, Chile August.
The Institutional Review Board. What is an IRB? An IRB is committee set up by an institution to review, approve, and regulate research conducted under.
Reporting Unanticipated Problems Involving Risk to Subjects or Others and Adverse Events WFUHS Policy/Procedure Effective Date 6/1/07 Wendy Murray Monitoring.
IRB Determinations 1. AAHRPP Site Visit Results Site visitors observed a real commitment to human subject protections Investigator and research staff.
Capturing and Reporting Adverse Events in Clinical Research
Pharmacists Responsibilities in Clinical Studies Mike R Sather, PhD Crystal L Harris, PharmD February 26, 2004.
John Naim, PhD Director Clinical Trials Research Unit
IRB-Investigator/ Research Coordinator Mtg. “CUMC’s New Progressive Policy For Adverse Event Reporting” April 13, 2004 George Gasparis Andrew Wit, Ph.D.
CUMC IRB Investigator Meeting Human Subjects Research Non-Compliance September 15, 2005.
Human Research Protection Program Training: Post-Approval Event Reporting March 26, 2008 Lisa Voss, MPH, CIP Assistant Director, QIU Human Research Protection.
Brookhaven Science Associates U.S. Department of Energy 1 Brookhaven National Laboratory Protocol Compliance Monitoring Darcy Mallon May 7, 2009.
HRPP Policies & Forms Created/Revised for AAHRPP.
Unlocking the Mystery of General Information Reporting Research Compliance Administration Training Presentation Wednesday, June 6, 2007 Presenter:Heather.
Institutional Review Board (IRB) Human Subject Research Office (HSRO) University of Miami and Affiliated Institutions.
Continuing Review VA Requirements Kevin L. Nellis, M.S., M.T. (A.S.C.P.) Program Analyst Program for Research Integrity Development and Education (PRIDE)
Federalwide Assurance Presentation for IRB Members.
Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?
SERIOUS ADVERSE EVENTS REPORTING Elizabeth Dayag IRB Administrator Naval Medical Center Portsmouth.
International Research & Research Involving Children K. Lynn Cates, MD Assistant Chief Research & Development Officer Office of Research & Development.
Adverse Events and Unanticipated Problems Presented by: Karen Jeans, PhD, CCRN, CIP COACH Program Analyst.
April 2011 Conducting Research at SPC Approval Process and Procedures Center of Excellence for Teaching and Learning.
ORO Reviews: Frequent Findings Related to IRBs Bob Brooks Associate Director Research Compliance Education and Policy VHA Office of Research Oversight.
Reporting Unanticipated Problems and Adverse Events: A Change in Policy Mary A. Banks RN, BS, BSN Director, BUMC IRB Wednesday, November 14, 2007.
Office of Research Oversight ORO Reporting Adverse Events in Research to ORO Paula Squire Waterman, MS, CIP Department of Veterans Affairs Office of Research.
EMORY INSTITUTIONAL REVIEW BOARD VERSION Unanticipated Problems, Protocol Deviations and Non-Compliance.
Common Audit Findings UTHSC Institutional Review Board (IRB)
Michelle Groy Johnson Quality Improvement Officer Research Integrity Office Tough Love: Understanding the Purpose and Processes of Quality Assurance.
Adverse Event/Unanticipated Problems Policy and Procedures November 2007.
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
Monitoring IRB Monitoring of Clinical Trials. Types of Monitoring Internally Internally Externally Externally.
East Tennessee State University. Full Accreditation Association for the Accreditation of Human Research Protection Programs (AAHRPP)
JERI R. BARNEY, JD HRPP COMPLIANCE MANAGER YALE UNIVERSITY HUMAN RESEARCH PROTECTION PROGRAM DECEMBER 13, 2012 Noncompliance.
TERRENCE F. ACKERMAN, PH.D. PROFESSOR OF BIOETHICS CHAIR, UTHSC IRB.
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
AUDIT REQUIREMENTS, FINDINGS & BASICS RESEARCH COMPLIANCE.
1 Unanticipated problems Melody Lin, Ph.D. December,
Continuing Review Presented by: Karen Jeans, PhD, CCRN, CIP Program Analyst, COACH.
Copyright FDA Inspections: Where Do Things Go Wrong? Diana Naser RN, MS, CCRP Executive Director Clinical Research Administration Clinical Research.
VHA Research Compliance Reporting Requirements ORD Accreditation Conference Call December 15, 2011.
Investigational Devices and Humanitarian Use Devices June 2007.
The NCI Central IRB Initiative Jacquelyn L. Goldberg, J.D. VA IRB Chair Training April 8, 2004.
HRPP Policies & Forms Chapter Two Created/Revised for AAHRPP June 1, 2007.
Office of Research Oversight 1 Office of Research and Development Local Accountability Meeting January 2009.
1 Auditing and Monitoring Gerald Beccia/RCO VA CT Healthcare System.
Human Subjects Protection Program Office of Research Compliance Navigating through the current HSPP and IRB Presented by: Danielle Griffin, M.S. Research.
INVESTIGATOR RESPONSIBILITIES C. Karen Jeans, MSN COACH Project Analyst.
Non-compliance with Human Subjects Research Regulations J. Bruce Smith, MD, CIP November 2014 Continuing Education for IRB Members.
The TJU Human Research Protection Program (HRPP) Part II, Conflict of Interest and IRB Noncompliance J. Bruce Smith, MD, CIP.
Marianne M. Elliott Office of Research Integrity and Ethics Bureau of Medicine and Surgery U. S Navy.
Slide 1 Standard Operating Procedures. Slide 2 Goal To review the standard operating procedures Creating the informed consent document Obtaining informed.
Good Clinical Practice (GCP) and Monitoring Practices
Instructions for New IRB Continuing Review (Progress) Report
Reportable Events Emory IRB 9/11/2014.
IRB reporting updates.
What is a Data and Safety Monitoring Plan and how do I get one?
Reportable Events & Other IRB Updates February 2017
UAMS Office of Research Compliance
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
Navigating Non-Compliance
SERIOUS ADVERSE EVENTS REPORTING
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
Reportable Events & Revised Common Rule
Event Reporting in Human Subjects Research
Policy on Prompt Reporting
Protocol Approval Criteria
Presentation transcript:

Gerald Treiman, IRB Chair John Stillman, IRB Director Maureen Brinkman, IRB Administrator Ann Johnson, IRB Administrator

Introduction to Reporting The Report Form is used to submit problems, events, and information to the IRB for review. Examples of problems or events include the following: Unexpected, related adverse events Deviations Adverse device effects Breaches of confidentiality or privacy Examples of information include the following: DSMB reports New information about the study that does not require and amendment Complaints from participants Warning or determination letters

The Report Review Process There are 3 levels of review that may occur: 1. Administrative review – conducted by Maureen Brinkman Starting point for all report forms EXCEPT adverse events 2. Subcommittee review – conducted by Ingrid Nygaard, Chris Stock, or Dennis O’Rourke Starting point for adverse events 3. Convened board review

Report Form Determinations Report forms are reviewed to make the following determinations Unanticipated problems (UPs) Non-compliance, not serious or continuing Serious and/or continuing non-compliance The administrative reviewer and subcommittee reviewer can make the following determinations: The report is NOT a UP The report is NOT non-compliance The report is non-compliance, but not serious or continuing

Report Form Determinations If the administrative reviewer or subcommittee reviewer believe the report is a UP or serious/continuing non-compliance, they forward it to the convened board. Only the convened board can make the following determinations: Unanticipated problems Serious and/or continuing non-compliance

Non-Compliance Review Process Can be initiated in the following ways: The PI tells us there is a deviation via the report form The IRB receives a complaint or other information that indicates there may be non-compliance If the review process is initiated by a complaint/concern, the IRB conducts an inquiry to verify that there is evidence of non- compliance. This may include: Interviews with study team members Audits of study records Collection of relevant data from other sources (e.g., OSP, FDA, Sponsor, etc.) All inquires are conducted in cooperation with the PI. After all relevant information is collected and evidence of non- compliance is established, the PI submits a report form for review.

Definitions Non-compliance: failure to abide by the policies, requirements, and determinations of the IRB, or federal rules and regulations including the requirements of the VHA Handbook governing human subject research. Serious N0n-Compliance: An act or omission to act that resulted in increased physical, psychological, safety, or privacy risk that compromised the rights and welfare of research participants. Continuing Non-Compliance: A pattern of repeated actions or omissions to act that suggests a future likelihood of reoccurrence and that indicates a deficiency in the ability or willingness to comply with federal regulations, VA [policy], requirements, and determinations of the IRB governing human subject research.

Report forms submitted: 2,767 Serious/Continuing Non-compliance Determinations: 10 The Numbers: Since January 2008 Admin Non-compliance Determinations: 448 Sub-C Non-compliance Determinations: 39

Protection of Research Participants It is the policy of the University of Utah IRB that before an administrative hold, suspension, or termination is put into effect the convened IRB or IRB designee considers whether any additional procedures need to be followed to protect the rights and welfare of current participants. These procedures may include but are not limited to: Submitting a list of all currently enrolled participants including their status within the study; Transferring participants to another investigator; Making arrangements for clinical care outside the research; Allowing continuation of some research activities under the supervision of an independent monitor; or Requiring or permitting follow-up of participants for safety reasons.

Suspensions & Terminations Suspension: A suspension of IRB approval is a directive of the convened IRB or IRB designee either to stop temporarily some or all previously approved research activities, or to stop permanently some previously approved research activities. Suspended protocols remain open and require continuing review. Termination: A termination of IRB approval is a directive of the convened IRB or IRB designee to stop permanently all activities in a previously approved research protocol. Terminated protocols are considered closed and no longer require continuing review.

Reference Materials IRB Website  Event Reporting IRB Website  SOPs 901: Unanticipated Problems Involving Risks to Participants and Others 902: Protocol Deviations 903: HRPP and Non-Compliance 904: Administrative Hold, Suspension, and Termination of Approved Research 905: Institutional Reporting Procedures 906: Protection of Research Participants 907: Research Complaints and Concerns 908: Routine and For-Cause Audits Board Reviewer Checklist  Report forms

Case Studies Determinations/Decisions Does the report represent serious non-compliance? Does the report represent continuing non-compliance? What are appropriate corrective actions? These should take into account how participants should be handled in order to prevent further risk, based upon the situation. Should the study be suspended or terminated?